XML 82 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Equity (Details Textual)
 1 Months Ended 12 Months Ended
Jul. 08, 2020
May 03, 2019
May 03, 2019
Mar. 12, 2019
Feb. 08, 2019
$ / shares
shares
Feb. 08, 2016
shares
Nov. 21, 2020
USD ($)
shares
Aug. 31, 2019
USD ($)
$ / shares
Jun. 30, 2019
USD ($)
shares
Feb. 28, 2017
Oct. 02, 2016
Aug. 26, 2016
USD ($)
May 06, 2016
Mar. 31, 2016
Mar. 21, 2016
$ / shares
shares
Feb. 17, 2016
shares
Oct. 31, 2015
USD ($)
Dec. 31, 2020
USD ($)
Investor
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Mar. 12, 2020
$ / shares
shares
May 26, 2017
USD ($)
Equity (Textual)                                          
Common stock, authorized                             360,000,000     100,000,000 100,000,000    
Common stock, par value | $ / shares                             $ 0.001     $ 0.001 $ 0.001    
Due to related parties | $                                   $ 288,445 $ 425,689    
Consulting fees | $                                     $ 4,514,800    
Common stock, shares issued                                   24,420,526 19,478,168    
Financial amendment, description   The Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.                                      
Agreement, description                   The Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).   The Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. The Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.                
Due to related parties consideration | $               $ 4,872,340                          
Common stock price per share | $ / shares               $ 7.00                          
Forward split ratio     The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split. i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes.                     1 to 3.141            
Subscription receivable | $                                 $ 350,000        
Stock subscription receivable | $                                   $ 40,751,807 $ 28,180,348    
Common Stock [Member]                                          
Equity (Textual)                                          
Issuance of common shares, shares                                     7,593,364    
Capital contributions                                   3,384,615      
Private Placement [Member]                                          
Equity (Textual)                                          
Aggregated capital contributions | $                                   $ 7,615,331      
Purchase price per share | $ / shares                                   $ 2.25      
Number of investors | Investor                                   45      
Note Holders [Member]                                          
Equity (Textual)                                          
Aggregated common shares                                   795,735      
2016 Equity Incentive Plan [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split                               50,000          
Common stock issued post-stock split                               157,050          
Share Exchange Agreement [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split           52,336,000                              
Common stock issued post-stock split           164,387,376                              
Share Exchange Agreement One [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split           52,936,583                              
Common stock issued post-stock split           166,273,921                              
Share Exchange Agreement Two [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split           51,945,225                              
Common stock issued post-stock split           163,159,952                              
Percentage of common shares issued and outstanding           79.70%                              
Percentage of issued share capital           100.00%                              
Share Exchange Agreement Three [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split           52,936,583                              
Common stock issued post-stock split           166,273,921                              
Exchange ratio           0.2536-for-1                              
Share Exchange Agreement Four [Member]                                          
Equity (Textual)                                          
Common stock issued pre-stock split           65,431,144                              
Common stock issued post-stock split           205,519,223                              
Collaborative Arrangement [Member]                                          
Equity (Textual)                                          
Issuance of common shares | $                 $ 3,000,000                        
Issuance of common shares, shares                 428,571                        
Consulting agreement, description                     The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000.                    
Collaborative Arrangement One [Member]                                          
Equity (Textual)                                          
Due to related parties | $                       $ 100,000,000                  
Percentage of payments under collaborative agreement                           6.50%              
Co-Dev Agreement [Member]                                          
Equity (Textual)                                          
Due to related parties | $                                         $ 3,000,000
Euro-Asia Investment & Finance Corp Ltd. [Member]                                          
Equity (Textual)                                          
Common stock, shares issued                                     644,972    
Stock subscription receivable | $                                   $ 4,063,320 $ 3,160,360    
BioKey [Member]                                          
Equity (Textual)                                          
Common stock issued post-stock split         1,642,291                                
Issuance of common shares, shares         29,561,231                                
Purchase price per share | $ / shares         $ 1.50                                
BioLite [Member]                                          
Equity (Textual)                                          
Issuance of common shares, shares         74,997,546                                
Articles of Incorporation [Member]                                          
Equity (Textual)                                          
Common stock, par value | $ / shares                                       $ 0.001  
View Trade Securities Inc [Member]                                          
Equity (Textual)                                          
Consulting fees | $                                   $ 135,000      
Common stock, shares issued                                   60,000      
Placement agent agreement, description The agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.                                        
Consulting Agreement [Member]                                          
Equity (Textual)                                          
Common stock price per share | $ / shares                                   $ 2.9      
Aggregated common shares                                   521,887      
Unrestricted common shares                                   50,000      
Non Related Parties [Member]                                          
Equity (Textual)                                          
Debt conversion, description                                   a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. b. The Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. c. The C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company's common stock, and warrants to purchase 162,908 shares of the Company's common stock. d. The KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company's common stock, and warrants to purchase 126,530 shares of the Company's common stock. e. The Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. f.The KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on April 5, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,212 shares of the Company’s common stock.      
Kameyama [Member]                                          
Equity (Textual)                                          
Issuance of common shares, shares             24,694                            
Unpaid consulting fees | $             $ 49,388                            
Maximum [Member] | Articles of Incorporation [Member]                                          
Equity (Textual)                                          
Common stock, authorized                                       100,000,000  
Maximum [Member] | Consulting Agreement [Member]                                          
Equity (Textual)                                          
Purchase price per share | $ / shares                                   $ 3.68      
Minimum [Member] | Articles of Incorporation [Member]                                          
Equity (Textual)                                          
Common stock, authorized                                       20,000,000  
Minimum [Member] | Consulting Agreement [Member]                                          
Equity (Textual)                                          
Purchase price per share | $ / shares                                   $ 2